The New Value Challenge: How to Accelerate Success in Oncology
It used to be enough to prove an oncology drug is safe and effective to gain market acceptance. Not anymore. Now sponsors must demonstrate product value. That means capturing the right data to address the diverse issues that payers, providers and patients care about – from the very beginning. What’s more, oncology is the toughest therapeutic area in which to prove value.
Learn how to satisfy the new demand for value.
New Health Library
Early Phase
-
Mapping the Future in Oncology Drug Development
Maximize drug development for optimal patient treatment.
-
Advancing Oncology Care Through Innovative Treatment Approaches
Shaping future treatment paradigms to improve patient survival.
- Integration of Molecular Biomarkers into Clinical Development
- From Biomarkers to Diagnostics - The Road to Success
- Biomarker Trends in Breast Cancer Research
- The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
- CardioCheck: A Biomarker Assay Program
- Translational R&D Services Fact Sheet
Drug Development
- Key Trends in Multiple Myeloma Treatment
- Oncology Expertise - Scientific Collaborator for Global Solutions
- Management of Tissue Specimens for Oncology Drug Development in China
- Oncology Nurse Educators - Groundbreaking Lessons
- Responsive Recruitment - Nimble Strategies for Changing Protocol
- Rapid Deployment - Oncology MSL Team Exceeds Expectations
- Recruiting Trust - Cancer Trial Enrollement Twice as Fast as Projected
- Strategic Response - Global Flexibility, Expertise and Network Avert Delays
Commercialization
- Oncology Drug Development and Value-Based Medicine
- A Blueprint for Clinical / Commercial Convergence
- New Voices and New Opportunities Toward Patient-Centric Model
- Market Intelligence and Analytics for Oncology
- Commercial – Identify, Promote and Prove Treatment Value
- Product Solutions - Partnering for Convergence Success
- Demonstrating Product Values
